1. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncol. 2021; 23(8): 1231-51. [DOI:10.1093/neuonc/noab106]

2. Stupp R, Hegi ME, Mason WP, Van Den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5): 459-66. [DOI:10.1016/S1470-2045(09)70025-7]

3. Li M, Deng H, Peng H, Wang Q. Functional Nanoparticles in Targeting Glioma Diagnosis and Therapies. J Nanosci Nanotechnol. 2014; 14(1): 415-32. [DOI:10.1166/jnn.2014.8757]

4. Masoomabadi N, Ebrahimi S, Noorbakhsh F, Tabibkhooei A, Mohaddes G, SadighEteghad S, et al. Expression of toll-like receptors and inflammatory mediators in primary human glioma cells low- and high-grade) compared to primary cells from epileptic human brain. Iran J Basic Med Sci [Internet]. 2025; 28(9).

5. Lathia JD, Mack SC, Mulkearns-Hubert EE, Valentim CLL, Rich JN. Cancer stem cells in glioblastoma. Genes Dev. 2015; 29(12): 1203-17. [DOI:10.1101/gad.261982.115]

6. Eshaghadadi arezou, Foroutan taereh, Gorji ali, Meshkinkhood noormohammad. Identifying Mechanisms of Radiation Resistance in Glioblastoma Using Bioinformatic and Molecular-Cellular Approaches. The Neuroscience Journal of Shefaye Khatam. 2025; 14(1): 51 EP -63. [DOI:10.61882/shefa.14.1.51]

7. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch Signaling: Cell Fate Control and Signal Integration in Development. Science. 1999; 284(5415): 770-6. [DOI:10.1126/science.284.5415.770]

8. Henrique D, Schweisguth F. Mechanisms of Notch signaling: a simple logic deployed in time and space. Development. 2019; 146(3): 172148. [DOI:10.1242/dev.172148]

9. Zhou B, Lin W, Long Y, Yang Y, Zhang H, Wu K, et al. Notch signaling pathway: architecture, disease, and therapeutics. Signal Transduct Target Ther. 2022; 7(1): 95. [DOI:10.1038/s41392-022-00934-y]

10. Parmigiani E, Taylor V, Giachino C. Oncogenic and Tumor-Suppressive Functions of NOTCH Signaling in Glioma. Cells. 2020; 9(10): 2304. [DOI:10.3390/cells9102304]

11. The Cancer Genome Atlas Research Network. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015; 372(26): 2481-98. [DOI:10.1056/NEJMoa1402121]

12. Wang SS, Lv HL, Nie RZ, Liu YP, Hou YJ, Chen C, et al. Notch signaling in cancer: metabolic reprogramming and therapeutic implications. Front Immunol. 2025; 16: 1656370. [DOI:10.3389/fimmu.2025.1656370]

13. Nie RZ, Wang H, Wang SS, Chen C, Luo HM, Zhang HK, et al. The role of notch signaling pathway and non-coding RNAs in cancer and inflammation: progress, therapeutic insights, and future directions. Front Immunol. 2025; 16: 1567040. [DOI:10.3389/fimmu.2025.1567040]

14. Wang S, Gu S, Chen J, Yuan Z, Liang P, Cui H. Mechanism of Notch Signaling Pathway in Malignant Progression of Glioblastoma and Targeted Therapy. Biomolecules. 2024; 14(4): 480. [DOI:10.3390/biom14040480]

15. Yi L, Zhou X, Li T, Liu P, Hai L, Tong L, et al. Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12/CXCR4. J Exp Clin Cancer Res. 2019; 38(1): 339. [DOI:10.1186/s13046-019-1319-4]

16. Li Y, Guessous F, Zhang Y, DiPierro C, Kefas B, Johnson E, et al. MicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes. Cancer Res. 2009; 69(19): 7569-76. [DOI:10.1158/0008-5472.CAN-09-0529]

17. Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci. 2008; 105(17): 6392-7. [DOI:10.1073/pnas.0802047105]

18. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455(7216): 1061-8. [DOI:10.1038/nature07385]

19. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci. 2006; 103(48): 18261-6. [DOI:10.1073/pnas.0606108103]

20. Xu R, Shimizu F, Hovinga K, Beal K, Karimi S, Droms L, et al. Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. Clin Cancer Res. 2016; 22(19): 4786-96. [DOI:10.1158/1078-0432.CCR-16-0048]

21. Majumder S, Crabtree JS, Golde TE, Minter LM, Osborne BA, Miele L. Targeting Notch in oncology: the path forward. Nat Rev Drug Discov. 2021; 20(2): 125-44. [DOI:10.1038/s41573-020-00091-3]

22. Kovall RA, Gebelein B, Sprinzak D, Kopan R. The Canonical Notch Signaling Pathway: Structural and Biochemical Insights into Shape, Sugar, and Force. Dev Cell. 2017; 41(3): 228-41. [DOI:10.1016/j.devcel.2017.04.001]

23. Deatherage CL, Lu Z, Kroncke BM, Ma S, Smith JA, Voehler MW, et al. Structural and biochemical differences between the Notch and the amyloid precursor protein transmembrane domains. Sci Adv. 2017; 3(4): e1602794. [DOI:10.1126/sciadv.1602794]

24. Chillakuri CR, Sheppard D, Lea SM, Handford PA. Notch receptor-ligand binding and activation: Insights from molecular studies. Semin Cell Dev Biol. 2012; 23(4): 421-8. [DOI:10.1016/j.semcdb.2012.01.009]

25. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7(9):678-89. [DOI:10.1038/nrm2009]

26. Kopan R, Ilagan MaXG. The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism. Cell. 2009; 137(2): 216-33. [DOI:10.1016/j.cell.2009.03.045]

27. Fortini ME. Notch Signaling: The Core Pathway and Its Posttranslational Regulation. Dev Cell. 2009; 16(5): 633-47. [DOI:10.1016/j.devcel.2009.03.010]

28. Ilagan MaXG, Lim S, Fulbright M, Piwnica-Worms D, Kopan R. Real-Time Imaging of Notch Activation with a Luciferase Complementation-Based Reporter. Sci Signal [Internet]. 2011; 4(181). [DOI:10.1126/scisignal.2001656]

29. Edelmann J, Holzmann K, Tausch E, Saunderson EA, Jebaraj BMC, Steinbrecher D, et al. Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription. Haematologica. 2020; 105(5): 1379-90. [DOI:10.3324/haematol.2019.217307]

30. Spriano F, Tarantelli C, Arribas AJ, Gaudio E, Cascione L, Aresu L, et al. In vitro anti‐lymphoma activity of the first‐in‐class PAN‐NOTCH transcription inhibitor CB ‐103. Br J Haematol. 2023; 200(5): 669-72. [DOI:10.1111/bjh.18576]

31. Portela M, Parsons LM, Grzeschik NA, Richardson HE. Regulation of Notch signaling and endocytosis by the Lgl neoplastic tumor suppressor. Cell Cycle. 2015; 14(10): 1496-506. [DOI:10.1080/15384101.2015.1026515]

32. Katoh M, Katoh M. Notch signaling in gastrointestinal tract (Review). Int J Oncol [Internet]. 2007. [DOI:10.3892/ijo.30.1.247]

33. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature. 2006; 444(7122): 1083-7. [DOI:10.1038/nature05313]

34. Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, MacSwords J, et al. Integrin Alpha 6 Regulates Glioblastoma Stem Cells. Cell Stem Cell. 2010; 6(5): 421-32. [DOI:10.1016/j.stem.2010.02.018]

35. Chen C, Du Y, Nie R, Wang S, Wang H, Li P. Notch signaling in cancers: mechanism and potential therapy. Front Cell Dev Biol. 2025; 13: 1542967. [DOI:10.3389/fcell.2025.1542967]

36. Poonaki E, Kahlert UD, Meuth SG, Gorji A. The role of the ZEB1-neuroinflammation axis in CNS disorders. J Neuroinflammation. 2022; 19(1): 275. [DOI:10.1186/s12974-022-02636-2]

37. Nieszporek A, Skrzypek K, Adamek G, Majka M. Molecular mechanisms of epithelial to mesenchymal transition in tumor metastasis. Acta Biochim Pol [Internet]. 2019. [DOI:10.18388/abp.2019_2899]

38. Saiki W, Ma C, Okajima T, Takeuchi H. Current Views on the Roles of O-Glycosylation in Controlling Notch-Ligand Interactions. Biomolecules. 2021; 11(2): 309. [DOI:10.3390/biom11020309]

39. Cordle J, RedfieldZ C, Stacey M, Van Der Merwe PA, Willis AC, Champion BR, et al. Localization of the Delta-like-1-binding Site in Human Notch-1 and Its Modulation by Calcium Affinity. J Biol Chem. 2008; 283(17): 11785-93. [DOI:10.1074/jbc.M708424200]

40. Luca VC, Kim BC, Ge C, Kakuda S, Wu D, Roein-Peikar M, et al. Notch-Jagged complex structure implicates a catch bond in tuning ligand sensitivity. Science. 2017; 355(6331): 1320-4. [DOI:10.1126/science.aaf9739]

41. Taylor P, Takeuchi H, Sheppard D, Chillakuri C, Lea SM, Haltiwanger RS, et al. Fringe-mediated extension of O -linked fucose in the ligand-binding region of Notch1 increases binding to mammalian Notch ligands. Proc Natl Acad Sci. 2014; 111(20): 7290-5. [DOI:10.1073/pnas.1319683111]

42. Gordon WR, Vardar-Ulu D, L'Heureux S, Ashworth T, Malecki MJ, Sanchez-Irizarry C, et al. Effects of S1 Cleavage on the Structure, Surface Export, and Signaling Activity of Human Notch1 and Notch2. Bergmann A, editor. PLoS ONE. 2009; 4(8): e6613. [DOI:10.1371/journal.pone.0006613]

43. Rand MD, Grimm LM, Artavanis-Tsakonas S, Patriub V, Blacklow SC, Sklar J, et al. Calcium Depletion Dissociates and Activates Heterodimeric Notch Receptors. Mol Cell Biol. 2000; 20(5): 1825-35. [DOI:10.1128/MCB.20.5.1825-1835.2000]

44. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, et al. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain. Nature. 1999; 398(6727): 518-22. [DOI:10.1038/19083]

45. Yi L, Zhou X, Li T, Liu P, Hai L, Tong L, et al. Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12/CXCR4. J Exp Clin Cancer Res. 2019; 38(1): 339. [DOI:10.1186/s13046-019-1319-4]

46. Tang J, Amin MA, Campian JL. Glioblastoma Stem Cells at the Nexus of Tumor Heterogeneity, Immune Evasion, and Therapeutic Resistance. Cells. 2025; 14(8): 562. [DOI:10.3390/cells14080562]

47. Shin HM, Minter LM, Cho OH, Gottipati S, Fauq AH, Golde TE, et al. Notch1 augments NF‐κB activity by facilitating its nuclear retention. EMBO J. 2006; 25(1): 129-38. [DOI:10.1038/sj.emboj.7600902]

48. Wongchana W, Kongkavitoon P, Tangtanatakul P, Sittplangkoon C, Butta P, Chawalitpong S, et al. Notch signaling regulates the responses of lipopolysaccharide-stimulated macrophages in the presence of immune complexes. Karpurapu M, editor. PLOS ONE. 2018; 13(6): e0198609. [DOI:10.1371/journal.pone.0198609]

49. Previs RA, Coleman RL, Harris AL, Sood AK. Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer. Clin Cancer Res. 2015; 21(5): 955-61. [DOI:10.1158/1078-0432.CCR-14-0809]

50. Agosti E, Antonietti S, Ius T, Fontanella MM, Zeppieri M, Panciani PP. Glioma Stem Cells as Promoter of Glioma Progression: A Systematic Review of Molecular Pathways and Targeted Therapies. Int J Mol Sci. 2024; 25(14): 7979. [DOI:10.3390/ijms25147979]

51. Zheng. Akt-mTOR signaling is involved in Notch-1-mediated glioma cell survival and proliferation. Oncol Rep [Internet]. 2010. [DOI:10.3892/or_00000782]

52. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, et al. Notch Promotes Radioresistance of Glioma Stem Cells. Stem Cells. 2010; 28(1): 17-28. [DOI:10.1002/stem.261]

53. Cao Y, Liu B, Cai L, Li Y, Huang Y, Zhou Y, et al. G9a promotes immune suppression by targeting the Fbxw7/Notch pathway in glioma stem cells. CNS Neurosci Ther. 2023; 29(9): 2508-21. [DOI:10.1111/cns.14191]

54. Panza S, Russo U, Giordano F, Leggio A, Barone I, Bonofiglio D, et al. Leptin and Notch Signaling Cooperate in Sustaining Glioblastoma Multiforme Progression. Biomolecules. 2020; 10(6): 886. [DOI:10.3390/biom10060886]

55. Hiddingh L, Tannous BA, Teng J, Tops B, Jeuken J, Hulleman E, et al. EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma. Oncotarget. 2014; 5(2): 363-74. [DOI:10.18632/oncotarget.1620]

56. Alafate W, Xu D, Wu W, Xiang J, Ma X, Xie W, et al. Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling. J Exp Clin Cancer Res. 2020; 39(1): 239. [DOI:10.1186/s13046-020-01750-4]

57. Inocencio J, Asad M, Aguilan J, Behnan J, Sidoli S, Himes B. STEM-16. Promoting The Cancer Stem Cell Subpopulation And Phenotype In Glioblastoma Via Extracellular Vesicle Cross-Talk.

58. Hiddingh L, Tannous BA, Teng J, Tops B, Jeuken J, Hulleman E, et al. EFEMP1 induces γ-secretase/Notch-mediated temozolomide resistance in glioblastoma. Oncotarget. 2014; 5(2): 363-74. [DOI:10.18632/oncotarget.1620]

59. Shih AH, Holland EC. Notch Signaling Enhances Nestin Expression in Gliomas. Neoplasia. 2006; 8(12): 1072-IN1. [DOI:10.1593/neo.06526]

60. Kanamori M, Kawaguchi T, Nigro JM, Feuerstein BG, Berger MS, Miele L, et al. Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg. 2007; 106(3): 417-27. [DOI:10.3171/jns.2007.106.3.417]

61. Yahyanejad S, King H, Iglesias VS, Granton PV, Barbeau LMO, Van Hoof SJ, et al. NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Oncotarget. 2106; 7(27): 41251-64. [DOI:10.18632/oncotarget.9275]

62. Hassanpourezatti M, Department of Biology, Faculty of Basic Sciences, Shahed University, Tehran, Iran, Nikookar Z, Department of Biology, Faculty of Basic Sciences, Shahed University, Tehran, Iran. Stem Cells and their Applications for the Treatment of Injuries to the Central Nervous System. Neurosci J Shefaye Khatam. 2021; 9(3): 116-29. [DOI:10.52547/shefa.9.3.116]

63. Qiu K, Ma C, Lu L, Wang J, Chen B, Mao H, et al. DAPT suppresses proliferation and migration of hepatocellular carcinoma by regulating the extracellular matrix and inhibiting the Hes1/PTEN/AKT/mTOR signaling pathway. J Gastrointest Oncol. 2021; 12(3): 1101-16. [DOI:10.21037/jgo-21-235]

64. Wang Y, Song W, Kan P, Huang C, Ma Z, Wu Q, et al. Overexpression of Epsin3 enhances migration and invasion of glioma cells by inducing epithelial‑mesenchymal transition. Oncol Rep [Internet]. 2018. [DOI:10.3892/or.2018.6691]

65. Sivasankaran B, Degen M, Ghaffari A, Hegi ME, Hamou MF, Ionescu MCS, et al. Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer Res. 2009; 69(2): 458-65. [DOI:10.1158/0008-5472.CAN-08-2610]

66. Ping Y, Yao X, Jiang J, Zhao L, Yu S, Jiang T, et al. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell‐mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. J Pathol. 2011; 224(3): 344-54. [DOI:10.1002/path.2908]

67. Gilbert CA, Daou MC, Moser RP, Ross AH. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res. 2010; 70(17): 6870-9. [DOI:10.1158/0008-5472.CAN-10-1378]

68. Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, et al. A High Notch Pathway Activation Predicts Response to γ Secretase Inhibitors in Proneural Subtype of Glioma Tumor-Initiating Cells. Stem Cells. 2014; 32(1): 301-12. [DOI:10.1002/stem.1528]

69. Yahyanejad S, King H, Iglesias VS, Granton PV, Barbeau LMO, van Hoof SJ, et al. NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Oncotarget. 2016; 7(27): 41251-64. [DOI:10.18632/oncotarget.9275]

70. Jung E, Osswald M, Ratliff M, Dogan H, Xie R, Weil S, et al. Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma. Nat Commun. 2021; 12(1): 1014. [DOI:10.1038/s41467-021-21117-3]

71. Charles N, Ozawa T, Squatrito M, Bleau AM, Brennan CW, Hambardzumyan D, et al. Perivascular Nitric Oxide Activates Notch Signaling and Promotes Stem-like Character in PDGF-Induced Glioma Cells. Cell Stem Cell. 2010; 6(2): 141-52. [DOI:10.1016/j.stem.2010.01.001]

72. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature. 2006; 444(7122): 1032-7. [DOI:10.1038/nature05355]

73. Li JL, Sainson RCA, Shi W, Leek R, Harrington LS, Preusser M, et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res. 2007;67(23):11244-53. [DOI:10.1158/0008-5472.CAN-07-0969]

74. Akil A, Gutiérrez-García AK, Guenter R, Rose JB, Beck AW, Chen H, et al. Notch Signaling in Vascular Endothelial Cells, Angiogenesis, and Tumor Progression: An Update and Prospective. Front Cell Dev Biol. 2021; 9: 642352. [DOI:10.3389/fcell.2021.642352]

75. Guelfi S, Hodivala-Dilke K, Bergers G. Targeting the tumour vasculature: from vessel destruction to promotion. Nat Rev Cancer. 2024; 24(10): 655-75. [DOI:10.1038/s41568-024-00736-0]

76. Shi Q, Xue C, Zeng Y, Yuan X, Chu Q, Jiang S, et al. Notch signaling pathway in cancer: from mechanistic insights to targeted therapies. Signal Transduct Target Ther. 2024; 9(1): 128. [DOI:10.1038/s41392-024-01828-x]

77. Fan X. γ-Secretase inhibitor-resistant glioblastoma stem cells require RBPJ to propagate. J Clin Invest. 2016; 126(7): 2415-8. [DOI:10.1172/JCI88619]

78. Liebelt BD, Shingu T, Zhou X, Ren J, Shin SA, Hu J. Glioma Stem Cells: Signaling, Microenvironment, and Therapy. Ulasov IV, editor. Stem Cells Int. 2016; 2016(1): 7849890. [DOI:10.1155/2016/7849890]

79. Jin J, Grigore F, Chen C, Li M. Self‑renewal signaling pathways and differentiation therapies of glioblastoma stem cells (Review). Int J Oncol. 2021; 59(1): 45. [DOI:10.3892/ijo.2021.5225]

80. Pistollato F, Rampazzo E, Persano L, Abbadi S, Frasson C, Denaro L, et al. Interaction of Hypoxia-Inducible Factor-1α and Notch Signaling Regulates Medulloblastoma Precursor Proliferation and Fate. Stem Cells. 2010; 28(11): 1918-29. [DOI:10.1002/stem.518]

81. Hu YY, Zheng MH, Cheng G, Li L, Liang L, Gao F, et al. Notch signaling contributes to the maintenance of both normal neural stem cells and patient-derived glioma stem cells. BMC Cancer. 2011; 11(1): 82. [DOI:10.1186/1471-2407-11-82]

82. Zheng X, Linke S, Dias JM, Zheng X, Gradin K, Wallis TP, et al. Interaction with factor inhibiting HIF-1 defines an additional mode of cross-coupling between the Notch and hypoxia signaling pathways. Proc Natl Acad Sci. 2008; 105(9): 3368-73. [DOI:10.1073/pnas.0711591105]

83. Irshad K, Mohapatra SK, Srivastava C, Garg H, Mishra S, Dikshit B, et al. A Combined Gene Signature of Hypoxia and Notch Pathway in Human Glioblastoma and Its Prognostic Relevance. Alonso MM, editor. PLOS ONE. 2015; 10(3): e0118201. [DOI:10.1371/journal.pone.0118201]

84. Ben-Shushan E, Feldman E, Reubinoff BE. Notch Signaling Regulates Motor Neuron Differentiation of Human Embryonic Stem Cells. Stem Cells. 2015; 33(2): 403-15. [DOI:10.1002/stem.1873]

85. Lin Y, Sun H, Dang Y, Li Z. Isoliquiritigenin inhibits the proliferation and induces the differentiation of human glioma stem cells. Oncol Rep [Internet]. 2017. [DOI:10.3892/or.2017.6154]

86. Cenciarelli C, Marei HE, Zonfrillo M, Casalbore P, Felsani A, Giannetti S, et al. The interference of Notch1 target Hes1 affects cell growth, differentiation and invasiveness of glioblastoma stem cells through modulation of multiple oncogenic targets. Oncotarget. 2017; 8(11): 17873-86. [DOI:10.18632/oncotarget.15013]

87. Ohtsuka T. Hes1 and Hes5 as Notch effectors in mammalian neuronal differentiation. EMBO J. 1999; 18(8): 2196-207. [DOI:10.1093/emboj/18.8.2196]

88. Saito N, Hirai N, Aoki K, Suzuki R, Fujita S, Nakayama H, et al. The Oncogene Addiction Switch from NOTCH to PI3K Requires Simultaneous Targeting of NOTCH and PI3K Pathway Inhibition in Glioblastoma. Cancers. 2019; 11(1): 121. [DOI:10.3390/cancers11010121]

89. Giordano F, D'Amico M, Montalto FI, Malivindi R, Chimento A, Conforti FL, et al. Cdk4 Regulates Glioblastoma Cell Invasion and Stemness and Is Target of a Notch Inhibitor Plus Resveratrol Combined Treatment. Int J Mol Sci. 2023; 24(12): 10094. [DOI:10.3390/ijms241210094]

90. Koury J, Zhong L, Hao J. Targeting Signaling Pathways in Cancer Stem Cells for Cancer Treatment. Stem Cells Int. 2017; 2017: 1-10. [DOI:10.1155/2017/2925869]

91. Ding D, Lim KS, Eberhart CG. Arsenic trioxide inhibits Hedgehog, Notch and stem cell properties in glioblastoma neurospheres. Acta Neuropathol Commun. 2014; 2(1): 31. [DOI:10.1186/2051-5960-2-31]

92. Krop I, Demuth T, Guthrie T, Wen PY, Mason WP, Chinnaiyan P, et al. Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors. J Clin Oncol. 2012; 30(19): 2307-13. [DOI:10.1200/JCO.2011.39.1540]

93. Behzad Basirat AM, Behzad Basirat Z, Rezaei Kia F, Ebrahimi S, Gorji A. Microglia: Structure, Function, and Role in the CNS. Neurosci J Shefaye Khatam. 2025; 13(4): 91-111. [DOI:10.61882/shefa.13.4.91]

94. Zhu TS, Costello MA, Talsma CE, Flack CG, Crowley JG, Hamm LL, et al. Endothelial Cells Create a Stem Cell Niche in Glioblastoma by Providing NOTCH Ligands That Nurture Self-Renewal of Cancer Stem-Like Cells. Cancer Res. 2011; 71(18): 6061-72. [DOI:10.1158/0008-5472.CAN-10-4269]

95. Li D, Masiero M, Banham AH, Harris AL. The notch ligand JAGGED1 as a target for anti-tumor therapy. Front Oncol. 2014; 4: 254. [DOI:10.3389/fonc.2014.00254]

96. Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, et al. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. 2019; 178(4): 835-849. [DOI:10.1016/j.cell.2019.06.024]

97. Wang Z, Zhang H, Xu S, Liu Z, Cheng Q. The adaptive transition of glioblastoma stem cells and its implications on treatments. Signal Transduct Target Ther. 2021; 6(1): 124. [DOI:10.1038/s41392-021-00491-w]

98. Gao F, Yao M, Shi Y, Hao J, Ren Y, Liu Q, et al. Notch pathway is involved in high glucose‐induced apoptosis in podocytes via Bcl‐2 and p53 pathways. J Cell Biochem. 2013; 114(5): 1029-38. [DOI:10.1002/jcb.24442]

99. Zhao Y, Deng B, Li Y, Zhou L, Yang L, Gou X, et al. Electroacupuncture Pretreatment Attenuates Cerebral Ischemic Injury via Notch Pathway-Mediated Up-Regulation of Hypoxia Inducible Factor-1α in Rats. Cell Mol Neurobiol. 2015; 35(8): 1093-103. [DOI:10.1007/s10571-015-0203-9]

100. Kwon OJ, Zhang L, Wang J, Su Q, Feng Q, Zhang XHF, et al. Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model. J Clin Invest. 2016; 126(7): 2626-41. [DOI:10.1172/JCI84637]

101. Drakos E, Singh RR, Rassidakis GZ, Schlette E, Li J, Claret FX, et al. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21). Leukemia. 2011; 25(5): 856-67. [DOI:10.1038/leu.2011.28]

102. Ladi E, Nichols JT, Ge W, Miyamoto A, Yao C, Yang LT, et al. The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands. J Cell Biol. 2005; 170(6): 983-92. [DOI:10.1083/jcb.200503113]

103. Spino M, Kurz SC, Chiriboga L, Serrano J, Zeck B, Sen N, et al. Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma. Clin Cancer Res. 2019; 25(4): 1261-71. [DOI:10.1158/1078-0432.CCR-18-2312]

104. Matsuo K, Taniguchi K, Hamamoto H, Inomata Y, Komura K, Tanaka T, et al. Delta‐like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview. Cancer Sci. 2021; 112(8): 2984-92. [DOI:10.1111/cas.15017]

105. Zhou W, Cheng L, Shi Y, Ke SQ, Huang Z, Fang X, et al. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth. Oncotarget. 2015; 6(35): 37300-15. [DOI:10.18632/oncotarget.5836]

106. Xia J, Li Y, Yang Q, Mei C, Chen Z, Bao B, et al. Arsenic Trioxide Inhibits Cell Growth and Induces Apoptosis through Inactivation of Notch Signaling Pathway in Breast Cancer. Int J Mol Sci. 2012; 13(8): 9627-41. [DOI:10.3390/ijms13089627]

107. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, et al. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst. 1998; 90(2): 124-33. [DOI:10.1093/jnci/90.2.124]

108. Lai IC, Shih PH, Yao CJ, Yeh CT, Wang-Peng J, Lui TN, et al. Elimination of Cancer Stem-Like Cells and Potentiation of Temozolomide Sensitivity by Honokiol in Glioblastoma Multiforme Cells. Debinski W, editor. PLOS ONE. 2015; 10(3): e0114830. [DOI:10.1371/journal.pone.0114830]

109. Ponnurangam S, Mammen JMV, Ramalingam S, He Z, Zhang Y, Umar S, et al. Honokiol in Combination with Radiation Targets Notch Signaling to Inhibit Colon Cancer Stem Cells. Mol Cancer Ther. 2012; 11(4): 963-72. [DOI:10.1158/1535-7163.MCT-11-0999]

110. Li M, Chen F, Clifton N, Sullivan DM, Dalton WS, Gabrilovich DI, et al. Combined Inhibition of Notch Signaling and Bcl-2/Bcl-xL Results in Synergistic Antimyeloma Effect. Mol Cancer Ther. 2010; 9(12): 3200-9. [DOI:10.1158/1535-7163.MCT-10-0372]

111. Li X, Liu B. FBXW7 in leukemia: A critical regulator of oncogenic stability and a potential therapeutic target. Tumor Discov. 2025; 4(3): 1. [DOI:10.36922/TD025150027]

112. Berghtold G, Dantas Barbosa C, Dieffenbach G, Daudigeos-Dubus E, Blokus H, Ferreira C, et al. NOTCH1 inhibition by the gamma-secretase inhibitor RO4929097 in pediatric glial tumors. J Clin Oncol. 2011; 29: 9555. [DOI:10.1200/jco.2011.29.15_suppl.9555]

113. Deng J, Liu AD, Hou GQ, Zhang X, Ren K, Chen XZ, et al. N-acetylcysteine decreases malignant characteristics of glioblastoma cells by inhibiting Notch2 signaling. J Exp Clin Cancer Res. 2019; 38(1): 2. [DOI:10.1186/s13046-018-1016-8]

114. Opačak-Bernardi T, Ryu JS, Raucher D. Effects of cell penetrating Notch inhibitory peptide conjugated to elastin-like polypeptide on glioblastoma cells. J Drug Target. 2017; 25(6): 523-31. [DOI:10.1080/1061186X.2017.1289537]

115. Zhang G, Tanaka S, Jiapaer S, Sabit H, Tamai S, Kinoshita M, et al. RBPJ contributes to the malignancy of glioblastoma and induction of proneural‐mesenchymal transition via IL‐6‐STAT3 pathway. Cancer Sci. 2020; 111(11): 4166-76. [DOI:10.1111/cas.14642]

116. Iser IC, Pereira MB, Lenz G, Wink MR. The Epithelial‐to‐Mesenchymal Transition‐Like Process in Glioblastoma: An Updated Systematic Review and In Silico Investigation. Med Res Rev. 2017; 37(2): 271-313. [DOI:10.1002/med.21408]

117. Xie M, Zhang L, He C, Xu F, Liu J, Hu Z, et al. Activation of notch‐1 enhances epithelial-mesenchymal transition in gefitinib‐acquired resistant lung cancer cells. J Cell Biochem. 2012; 113(5): 1501-13. [DOI:10.1002/jcb.24019]

118. Zeng Z, Fu M, Hu Y, Wei Y, Wei X, Luo M. Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer. Mol Cancer. 2023; 22(1): 172. [DOI:10.1186/s12943-023-01877-w]

119. Qin HY, Fu LA, Han H. Regulation of Glioma Stem Cells by the Notch Signaling Pathway: Mechanisms and Therapeutic Implications. In: Shostak S, editor. Cancer Stem Cells - The Cutting Edge [Internet]. London: IntechOpen; 2011.

120. Dong M, Zhang X, Peng P, Chen Z, Zhang Y, Wan L, et al. Hypoxia-induced TREM1 promotes mesenchymal-like states of glioma stem cells via alternatively activating tumor-associated macrophages. Cancer Lett. 2024; 590: 216801. [DOI:10.1016/j.canlet.2024.216801]

121. Braune EB, Geist F, Tang X, Kalari K, Boughey J, Wang L, et al. Identification of a Notch transcriptomic signature for breast cancer. Breast Cancer Res. 2024; 26(1): 4. [DOI:10.1186/s13058-023-01757-7]

122. Sorrentino C, Cuneo A, Roti G. Therapeutic Targeting of Notch Signaling Pathway in Hematological Malignancies. Mediterr J Hematol Infect Dis. 2019; 11(1): e2019037. [DOI:10.4084/mjhid.2019.037]

123. Lu Z, Ren Y, Zhang M, Fan T, Wang Y, Zhao Q, et al. FLI-06 suppresses proliferation, induces apoptosis and cell cycle arrest by targeting LSD1 and Notch pathway in esophageal squamous cell carcinoma cells. Biomed Pharmacother. 2018; 107: 1370-6. [DOI:10.1016/j.biopha.2018.08.140]

124. Giovannini C, Bolondi L, Gramantieri L. Targeting Notch3 in Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Perspectives. Int J Mol Sci. 2016; 18(1): 56. [DOI:10.3390/ijms18010056]

125. Zhou J, Meng N, Lu L, Lu J, Wu S, Ding Y, et al. A novel peptide-drug conjugate for glioma-targeted drug delivery. J Control Release Off J Control Release Soc. 2024; 369: 722-33. [DOI:10.1016/j.jconrel.2024.04.011]

126. Liao J, Fan L, Li Y, Xu QQ, Xiong LY, Zhang SS, et al. Recent advances in biomimetic nanodelivery systems: New brain-targeting strategies. J Control Release Off J Control Release Soc. 2023; 358: 439-64. [DOI:10.1016/j.jconrel.2023.05.009]

127. Mizoguchi A, Takayama A, Arai T, Kida Y, Kawauchi J, Sudo H. Abstract 510: MicroRNA-8073 as a tumor suppressor and a potential diagnostic and therapeutic target. Cancer Res. 2018; 78: 510-510. [DOI:10.1158/1538-7445.AM2018-510]

128. Yuan X, Wu H, Xu H, Xiong H, Chu Q, Yu S, et al. Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett. 2015; 369(1): 20-7. [DOI:10.1016/j.canlet.2015.07.048]

129. Banu MA, Dovas A, Cuervo H, Pereira B, Mahajan A, Ding H, et al. Abstract 5103: Notch is a master regulator of mesenchymal transformation and therapeutic resistance in glioma. Cancer Res. 2018; 78: 5103-5103. [DOI:10.1158/1538-7445.AM2018-5103]

130. Cai J, Qiao Y, Chen L, Lu Y, Zheng D. Regulation of the Notch signaling pathway by natural products for cancer therapy. J Nutr Biochem. 2024; 123: 109483. [DOI:10.1016/j.jnutbio.2023.109483]

131. Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, et al. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle. 2010; 9(6): 1031-6. [DOI:10.4161/cc.9.6.10987]

132. Li WB, Ma MW, Dong LJ, Wang F, Chen LX, Li XR. MicroRNA-34a targets notch1 and inhibits cell proliferation in glioblastoma multiforme. Cancer Biol Ther. 2011; 12(6): 477-83. [DOI:10.4161/cbt.12.6.16300]

133. Xu H, Zhang Y, Qi L, Ding L, Jiang H, Yu H. NFIX Circular RNA Promotes Glioma Progression by Regulating miR-34a-5p via Notch Signaling Pathway. Front Mol Neurosci. 2018; 11: 225. [DOI:10.3389/fnmol.2018.00225]

134. Zhao C, Guo R, Guan F, Ma S, Li M, Wu J, et al. MicroRNA-128-3p Enhances the Chemosensitivity of Temozolomide in Glioblastoma by Targeting c-Met and EMT. Sci Rep. 2020; 10(1): 9471. [DOI:10.1038/s41598-020-65331-3]

135. Xu J, Song J, Xiao M, Wang C, Zhang Q, Yuan X, et al. RUNX1 (RUNX family transcription factor 1), a target of microRNA miR-128-3p, promotes temozolomide resistance in glioblastoma multiform by upregulating multidrug resistance-associated protein 1 (MRP1). Bioengineered. 2021; 12(2): 11768-81. [DOI:10.1080/21655979.2021.2009976]

136. Yi Q, Yue J, Liu Y, Shi H, Sun W, Feng J, et al. Recent advances of exosomal circRNAs in cancer and their potential clinical applications. J Transl Med. 2023; 21(1): 516. [DOI:10.1186/s12967-023-04348-4]

137. Zhang S, Guo S, Liang C, Lian M. Long intergenic noncoding RNA 00021 promotes glioblastoma temozolomide resistance by epigenetically silencing p21 through Notch pathway. IUBMB Life. 2020; 72(8): 1747-56. [DOI:10.1002/iub.2301]

138. He Z, Zhong Y, Regmi P, Lv T, Ma W, Wang J, et al. Exosomal long non-coding RNA TRPM2-AS promotes angiogenesis in gallbladder cancer through interacting with PABPC1 to activate NOTCH1 signaling pathway. Mol Cancer. 2024; 23(1): 65. [DOI:10.1186/s12943-024-01979-z]

139. Masoomabadi N, Gorji A, Ghadiri T, Ebrahimi S. Regulatory role of circular RNAs in the development of therapeutic resistance in the glioma: A double-edged sword. Iran J Basic Med Sci [Internet]. 2025; 28(1).

140. Golabi F, Malekpour M, Midjani F, Kashkooli M, Behrouzi B. Correlation between computational insights into non-coding RNA regulatory networks and glioblastoma survival. J Clin Oncol [Internet]. 2025;43(16_suppl). [DOI:10.1200/JCO.2025.43.16_suppl.e14028]

141. Li Y, Ren Y, Wang Y, Tan Y, Wang Q, Cai J, et al. A Compound AC1Q3QWB Selectively Disrupts HOTAIR-Mediated Recruitment of PRC2 and Enhances Cancer Therapy of DZNep. Theranostics. 2019; 9(16): 4608-23. [DOI:10.7150/thno.35188]

142. Wang W, Zhou Y, Wang J, Zhang S, Ozes A, Gao H, et al. Targeting Ovarian Cancer Stem Cells by Dual Inhibition of the Long Noncoding RNA HOTAIR and Lysine Methyltransferase EZH2. Mol Cancer Ther. 2024; 23(11): 1666-79. [DOI:10.1158/1535-7163.MCT-23-0314]

143. Fang K, Liu P, Dong S, Guo Y, Cui X, Zhu X, et al. Magnetofection based on superparamagnetic iron oxide nanoparticle-mediated low lncRNA HOTAIR expression decreases the proliferation and invasion of glioma stem cells. Int J Oncol. 2016; 49(2): 509-18. [DOI:10.3892/ijo.2016.3571]

144. Wasson CW, Ross RL, Wells R, Corinaldesi C, Georgiou ICh, Riobo-Del Galdo NA, et al. Long non-coding RNA HOTAIR induces GLI2 expression through Notch signalling in systemic sclerosis dermal fibroblasts. Arthritis Res Ther. 2020; 22(1): 286. [DOI:10.1186/s13075-020-02376-9]

145. Wang J, Li T, Wang B. Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7. Int J Oncol. 2021; 59(2): 64. [DOI:10.3892/ijo.2021.5244]

146. Vieira de Castro J, Gonçalves CS, Hormigo A, Costa BM. Exploiting the Complexities of Glioblastoma Stem Cells: Insights for Cancer Initiation and Therapeutic Targeting. Int J Mol Sci. 2020; 21(15): 5278. [DOI:10.3390/ijms21155278]

147. Huang X, Shi S, Wang H, Zhao T, Wang Y, Huang S, et al. Advances in antibody-based drugs and their delivery through the blood-brain barrier for targeted therapy and immunotherapy of gliomas. Int Immunopharmacol. 2023; 117: 109990. [DOI:10.1016/j.intimp.2023.109990]

148. Herrera-Rios D, Li G, Khan D, Tsiampali J, Nickel AC, Aretz P, et al. A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma. Sci Rep. 2020; 10(1): 16218. [DOI:10.1038/s41598-020-72480-y]

149. Cong P, Wu T, Huang X, Liang H, Gao X, Tian L, et al. Identification of the Role and Clinical Prognostic Value of Target Genes of m6A RNA Methylation Regulators in Glioma. Front Cell Dev Biol. 2021; 9: 709022. [DOI:10.3389/fcell.2021.709022]

150. Zhang L, Li F, Zhang L, Zhou Y, Liu Y, Liu J, et al. KIF18B drives the malignant progression of gliomas by activating the Notch pathway. Cell Signal. 2025; 134: 111888. [DOI:10.1016/j.cellsig.2025.111888]

151. Yang Q, Deng L, Li J, Miao P, Liu W, Huang Q. NR5A2 Promotes Cell Growth and Resistance to Temozolomide Through Regulating Notch Signal Pathway in Glioma. OncoTargets Ther. 2020; 13: 10231-44. [DOI:10.2147/OTT.S243833]

152. Shen N, Lv W, Li S, Liu D, Xie Y, Zhang J, et al. Noninvasive Evaluation of the Notch Signaling Pathway via Radiomic Signatures Based on Multiparametric MRI in Association With Biological Functions of Patients With Glioma: A MULTI‐INSTITUTIONAL Study. J Magn Reson Imaging. 2023; 57(3): 884-96. [DOI:10.1002/jmri.28378]

153. Patel D, Wairkar S, Yergeri MC. Current Developments in Targeted Drug Delivery Systems for Glioma. Curr Pharm Des. 2020; 26(32): 3973-84. [DOI:10.2174/1381612826666200424161929]

154. Akbar Samadani A, Keymoradzdeh A, Shams S, Soleymanpour A, Elham Norollahi S, Vahidi S, et al. Mechanisms of cancer stem cell therapy. Clin Chim Acta Int J Clin Chem. 2020; 510: 581-92. [DOI:10.1016/j.cca.2020.08.016]

155. Rani V, Venkatesan J, Prabhu A. Nanotherapeutics in glioma management: Advances and future perspectives. J Drug Deliv Sci Technol. 2020; 57: 101626. [DOI:10.1016/j.jddst.2020.101626]

156. Min W, Zou C, Dai D, Zuo Q, Chen C, Xu J, et al. Integrin Beta 1 Promotes Glioma Cell Proliferation by Negatively Regulating the Notch Pathway. J Oncol. 2020; 2020: 8297017. [DOI:10.1155/2020/8297017]

157. Xia X, Wang Z, Song L, Cheng Y, Xiong P, Li S. FAM3C Regulates Glioma Cell Proliferation, Invasion, Apoptosis, and Epithelial Mesenchymal Transition via the Notch Pathway. Cancer Med. 2024; 13(23): e70412. [DOI:10.1002/cam4.70412]

158. Aggarwal V, Tuli HS, Varol M, Tuorkey M, Sak K, Parashar NC, et al. NOTCH signaling: Journey of an evolutionarily conserved pathway in driving tumor progression and its modulation as a therapeutic target. Crit Rev Oncol Hematol. 2021; 164: 103403. [DOI:10.1016/j.critrevonc.2021.103403]

159. Ferreira A, Aster JC. Notch signaling in cancer: Complexity and challenges on the path to clinical translation. Semin Cancer Biol. 2022; 85: 95-106. [DOI:10.1016/j.semcancer.2021.04.008]

160. Casili G, Lanza M, Filippone A, Caffo M, Paterniti I, Campolo M, et al. Overview on Common Genes Involved in the Onset of Glioma and on the Role of Migraine as Risk Factor: Predictive Biomarkers or Therapeutic Targets? J Pers Med. 2022; 12(12): 1969. [DOI:10.3390/jpm12121969]

161. Jiang H, Bian W, Sui Y, Li H, Zhao H, Wang W, et al. FBXO42 facilitates Notch signaling activation and global chromatin relaxation by promoting K63-linked polyubiquitination of RBPJ. Sci Adv. 2022; 8(38): eabq4831. [DOI:10.1126/sciadv.abq4831]

162. Hong J, Gu R, Cheng W, Lu C, Wang X. LncRNA MACC1-AS1 facilitates the cell growth of small cell lung cancer by sequestering miR-579-3p and mediating NOTCH1-pathway. Int J Biol Macromol. 2024; 281: 136579. [DOI:10.1016/j.ijbiomac.2024.136579]

163. Parmigiani E, Ivanek R, Rolando C, Hafen K, Turchinovich G, Lehmann FM, et al. Interferon-γ resistance and immune evasion in glioma develop via Notch-regulated co-evolution of malignant and immune cells. Dev Cell. 2022; 57(15): 1847-1865. [DOI:10.1016/j.devcel.2022.06.006]

164. You WK, Schuetz TJ, Lee SH. Targeting the DLL/Notch Signaling Pathway in Cancer: Challenges and Advances in Clinical Development. Mol Cancer Ther. 2023; 22(1): 3-11. [DOI:10.1158/1535-7163.MCT-22-0243]

165. Vazquez-Arreguin K, Otani Y, Rivera-Caraballo K, Kaur B. TMIC-61. DEVELOPMENT OF A NOVEL NOTCH-TARGETING ONCOLYTIC HSV FOR GBM TUMORS. Neuro-Oncol. 2024; 26. [DOI:10.1093/neuonc/noae165.1239]

166. Messerschmidt VL, Chintapula U, Kuriakose AE, Laboy S, Truong TTD, Kydd LA, et al. Notch Intracellular Domain Plasmid Delivery via Poly(Lactic-Co-Glycolic Acid) Nanoparticles to Upregulate Notch Pathway Molecules. Front Cardiovasc Med. 2021; 8: 707897. [DOI:10.3389/fcvm.2021.707897]

167. Zhang G, Yao M, Ma S, Zhang K, Wang Y, Wang Z, et al. Application of cell membrane-functionalized biomimetic nanoparticles in the treatment of glioma. J Mater Chem B. 2023; 11(30): 7055-68. [DOI:10.1039/D3TB00605K]

168. Zhang F, Wen C, Peng Y, Hu Z, Zheng S, Chen W, et al. Biomimetic lipid nanoparticles for homologous-targeting and enhanced photodynamic therapy against glioma. Eur J Pharm Sci. 2023; 190: 106574. [DOI:10.1016/j.ejps.2023.106574]

169. Chen KY, Bush K, Klein RH, Cervantes V, Lewis N, Naqvi A, et al. Reciprocal H3.3 gene editing identifies K27M and G34R mechanisms in pediatric glioma including NOTCH signaling. Commun Biol. 2020; 3(1): 363. [DOI:10.1038/s42003-020-1076-0]

170. Wu H, Wei M, Li Y, Ma Q, Zhang H. Research Progress on the Regulation Mechanism of Key Signal Pathways Affecting the Prognosis of Glioma. Front Mol Neurosci. 2022; 15: 910543. [DOI:10.3389/fnmol.2022.910543]

171. Ghaffarian Zirak R, Tajik H, Asadi J, Hashemian P, Javid H. The Role of Micro RNAs in Regulating PI3K/AKT Signaling Pathways in Glioblastoma. Iran J Pathol. 2022; 17(2): 122-36. [DOI:10.30699/ijp.2022.539029.2726]

172. D'Amico M, De Amicis F. Aberrant Notch signaling in gliomas: a potential landscape of actionable converging targets for combination approach in therapies resistance. Cancer Drug Resist. 2022; 5: 939-53. [DOI:10.20517/cdr.2022.46]

173. Hersh AM, Gaitsch H, Alomari S, Lubelski D, Tyler BM. Molecular Pathways and Genomic Landscape of Glioblastoma Stem Cells: Opportunities for Targeted Therapy. Cancers. 2022; 14(15): 3743. [DOI:10.3390/cancers14153743]